Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company dedicated to developing and commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs, recently announced that a research article on the anti-tumor activity of RX-8243 and its analogues has been published in Bioorganic & Medicinal Chemistry Letters.

The article suggests that RX-8243, an isoquinolineamine analogue, significantly inhibits the growth of human cancer cells, including paclitaxel (Taxol®) resistant HCT-15 human colorectal cancer cells. The study demonstrates that RX-8243 inhibited tumor formation in paclitaxel-resistant cancer model, which suggests that isoquinolineamine and its analogues have the potential to become a novel class of anti-tumor chemotherapeutics.

Chang Ahn, chief executive officer of Rexahn Pharmaceuticals, Inc., stated, “We are encouraged by the results of this study of RX-8243, which shows the potent anti-tumor properties of this unique compound. The study clearly demonstrates that RX-8243 inhibited tumor formation in paclitaxel-resistant cancer model, suggesting that isoquinolineamine and its analogues have the potential to become a novel class of anti-tumor chemotherapeutics.”

For more information, please visit www.rexahn.com.

Let us hear your thoughts below: